In relapsed or refractory Hodgkin's lymphoma, PD‐L1 and/or PD‐L2 were often amplified in Reed–Sternberg cells and these patients showed substantial therapeutic response to PD‐L1 inhibitor Nivolumab [8]. This evidence concerns the gene CD274 and Hodgkins lymphoma.